Recombinant Lactococcus Lactis Displaying Omp31 Antigen of Brucella melitensis Can Induce an Immunogenic Response in BALB/c Mice
- 13 July 2020
- journal article
- research article
- Published by Springer Nature in Probiotics and Antimicrobial Proteins
- Vol. 13 (1) , 80-89
Abstract
Since Brucella infection mostly occurs through the mucosal surfaces, immune response induced by vaccine that is delivered by a way of mucosal route can be drastically enhanced to control the brucellosis. Omp31is the major outer membrane protein of Brucella, and is considered as a protective antigen against Brucella infection. Accordingly, Lactococcus lactis has been used as an antigen-delivering vector to develop a vaccine-induced mucosal response for having a safer vaccination against brucellosis. A designed omp31 gene fused to the usp45 signal peptide and M6 cell wall anchor was sub cloned in the pNZ7021 expression vector, and a recombinant L. lactis displaying Omp31 was constructed. Omp31 protein expression was confirmed using Western blotting and immunofluorescence analysis. Animals were orally and intraperitoneally immunized with live or killed L. lactis expressing Omp31, respectively. The humoral and cellular immune responses were evaluated by measuring the specific cytokines and antibodies. sIgA, serum IgA, IgM, and total IgG antibodies significantly increased in the mice immunized with live recombinant L. lactis expressing Omp31 and also serum IgM, and total IgG antibodies significantly increased in mice immunized with killed recombinant L. lactis expressing Omp31. Among IgG subtypes, IgG2a response was significantly higher in both groups compared to IgG1. In mice groups immunized with recombinant L. lactis, the IFN-γ and IL-10 level elevated; however, there was no change in the level of IL-4. These results indicated that recombinants L. lactis induce both humoral and cellular immune responses in mice, and also vaccines based on L. lactis-derived live carriers are promising interventions against Brucella melitensis infections.Keywords
Funding Information
- Zanjan University of Medical Sciences (A- 12-873-7)
This publication has 45 references indexed in Scilit:
- Invasive Escherichia coli vaccines expressing Brucella melitensis outer membrane proteins 31 or 16 or periplasmic protein BP26 confer protection in mice challenged with B. melitensisVaccine, 2012
- Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in miceJournal of Clinical Investigation, 2012
- Lactococcus lactis-based vaccines from laboratory bench to human use: An overviewVaccine, 2012
- Induction of Immune Responses in Mice after Oral Immunization with RecombinantLactobacillus caseiStrains Expressing EnterotoxigenicEscherichia coliF41 Fimbrial ProteinApplied and Environmental Microbiology, 2009
- Oral immunization with recombinant Lactococcus lactis confers protection against respiratory pneumococcal infectionCanadian Journal of Microbiology, 2008
- Complete Genome Sequence of the Prototype Lactic Acid Bacterium Lactococcus lactis subsp. cremoris MG1363Journal of Bacteriology, 2007
- Characterization of the Role of para- Aminobenzoic Acid Biosynthesis in Folate Production by Lactococcus lactisApplied and Environmental Microbiology, 2007
- BrucellosisNew England Journal of Medicine, 2005
- Role of Interleukin-4 (IL-4) and IL-10 in Serum Immunoglobulin G Antibody Responses following Mucosal or Systemic Reovirus InfectionJournal of Virology, 2004
- Structure and Function of Human and Murine Receptors for IgGAnnual Review of Immunology, 1988